Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the INFECTIOTEK biobank will be to prospectively build a biobank of multiple biological samples from patients with infectious diseases in order to identify diagnostic and prognostic biomarkers, genetic susceptibility factors and immune response mechanisms in such diseases.
The population of the study will consist of patients treated in the Infectious Diseases Departments of Saint-Louis and Lariboisière Hospitals, with a diagnosis of infectious disease, and who have biological samples in the context of their routine medical care.
The diseases studied in this research project are bacterial infections (urinary tract infections, neurologic infections, sexually transmitted infections, pulmonary infections), viral infections (HIV, hepatitis, respiratory viruses, viruses affecting immunocompromised patients) and fungal infections (Aspergillus, Mucorales, Cryptococcus). These diseases are the domains of expertise and research of the clinical and biological teams at the Saint-Louis and Lariboisière hospitals.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients diagnosed with an infectious disease |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sampling | Other | Additional biological sampling at the same time as routine-care samples taken in the context of the diagnosis of the infectious disease and if planned at one and 12 months of follow-up
|
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic performances of new biomarkers to identify infection | Sensitivity, Specificity, Positive Predictive Value, Negative Predictive Value, Positive Likelihood Ratio, Negative Likelihood Ratio of the new biomarker | At diagnosis |
| Measure | Description | Time Frame |
|---|---|---|
| Description of pathophysiological phenomena | Resistance mechanisms, virulence parameters, immune responses to the infectious agent, susceptibility factors to infections | Until 12 months |
| Description of prognostic biomarkers |
Not provided
Inclusion Criteria:
Patient over 18 years of age
Diagnosed with one of the following infectious diseases :
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients treated in the Infectious Diseases Departments of Saint-Louis and Lariboisière Hospitals, with a diagnosis of infectious disease, and who have biological samples in the context of their routine medical care
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Emma Rubenstein, MD | Contact | 142499066 | +33 | emma.rubenstein@aphp.fr |
| Jérôme Lambert, MD PhD | Contact | 142499742 | +33 | jerome.lambert@u-paris.fr |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D003141 | Communicable Diseases |
| D009181 | Mycoses |
| ID | Term |
|---|---|
| D007239 | Infections |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood sampling
In addition, infection site sampling according to pathology :
|
| Until 12 months |
| D001423 | Bacterial Infections and Mycoses |